If Antibody-drug conjugates (ADC) and PD-1 Inhibitors are used in combination, what kind of sparks will be created?
Currently, there are a variety of drugs available for multiple myeloma, including traditional cytotoxic drugs, immunomodulatory analogs, proteasome inhibitors, antibody-based drugs and CAR T-…
In this article, we will introduce the preclinical data of some currently known bispecific ADC drugs in clinical or preclinical.
Herein, we review the approved and investigational ADCs that target HER family receptors, including EGFR, HER2 and HER3.
FRα will become another hot target in ADC field. As with PD1, once it is successful in one indication, it can be replicated for more indications.
At present, GLP-1R targeted drugs have occupied half of the field of hypoglycemia and weight loss, while GLP-1R, GCGR, GIPR, FGF21 dual-target and multi-target drugs have also entered the fie…
Semaglutide may have the potential to protect against cardiovascular disease, treat NAFLD, fight cancer, alleviate neurodegenerative diseases and reduce addictive behaviors, etc.
The bystander effect of ADC is expected to solve heterogeneous expression of target antigens (Ag) in metastatic tumor tissues.
Glucagon-like peptide-1 (GLP-1), as one of the important targets for the treatment of type 2 diabetes mellitus (T2DM), has obvious therapeutic effect, short half-life and easy to be cleared. …
ADC payloads are critical components of the ADC structure, and their selection and design are crucial for achieving optimal therapeutic efficacy and minimizing toxicity.